FMTXCT
Hybrid Fluorescence Molecular Tomography and X-ray Computed Tomography system and method
| Coordinatore | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.fmt-xct.eu |
| Totale costo | 5˙839˙676 € |
| EC contributo | 4˙512˙141 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2012-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | coordinator | 0.00 |
| 2 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
| 3 |
CT Imaging GmbH
Organization address
address: Henkestrasse, 91 contact info |
DE (ERLANGEN) | participant | 0.00 |
| 4 |
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
Organization address
address: N PLASTIRA STR 100 contact info |
EL (HERAKLION) | participant | 0.00 |
| 5 |
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON
Organization address
address: c/ Dr. Esquerdo contact info |
ES (MADRID) | participant | 0.00 |
| 6 |
UNIVERSIDAD CARLOS III DE MADRID
Organization address
address: CALLE MADRID 126 contact info |
ES (GETAFE (MADRID)) | participant | 0.00 |
| 7 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 0.00 |
| 8 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This proposal offers to combine X-ray CT (XCT) and Fluorescence Molecular Tomography (FMT) into a hybrid, quantitative system and method. The project builds on state-of the-art knowledge that only recently became available in different European states as represented by the partners herein. In return it delivers the first such hybrid system worldwide. The system will operate by 1) co-registering XCT images with highly performing FMT images for merging anatomical, functional and molecular contrast and by 2) combining XCT information into the FMT inversion to provide a system with superior imaging performance. XCT-based correction, as explained in this proposal, can improve FMT performance in a more radical way than corresponding “correction methods” used for improving PET or SPECT images. In this way FMT-XCT can reach the imaging accuracy of radio-nuclei-based tomography hybrid systems. By using fluorescence, FMT-XCT can then enable high flexibility in targeting physiology and molecular function, especially in multi-spectral mode, and high dissemination potential because virtually any biomedical laboratory has access to fluorescence reporting, compared to radio-nuclei based research that requires access to radiochemistry and cyclotron facilities. FMT-XCT aims in advancing small animal imaging and drug discovery with a view towards the clinical application on non-invasive breast cancer imaging. For this reason, focus herein is given to imaging breast cancer and response to therapy. Overall the technology is ideally suited for commercial translation and has the potential to become the method of choice for in-vivo imaging in most biomedical laboratories and in select clinical applications. While it appreciates the value of nuclear imaging methods, this proposal will hopefully raise the funding necessary to establish on European ground a new potent paradigm of in-vivo imaging with high dissemination and application potential and large social and health-care impact .'
Introduzione (Teaser)
Accurate diagnosis is one issue; appropriate therapy is another. Together, they are the key to eradication of many diseases. With EU funding, researchers have pioneered a hybrid imaging technique to achieve both ambitious objectives.